Radius Health Inc (NASDAQ:RDUS)’s share price shot up 10.1% during mid-day trading on Thursday . The stock traded as high as $16.12 and last traded at $16.12. 681,694 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 842,786 shares. The stock had previously closed at $14.64.
Several brokerages have recently issued reports on RDUS. Jefferies Financial Group reaffirmed a “hold” rating and issued a $25.00 price objective on shares of Radius Health in a research note on Tuesday, August 7th. Cowen reaffirmed a “hold” rating on shares of Radius Health in a research note on Thursday, October 18th. Zacks Investment Research cut shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. JPMorgan Chase & Co. lowered their price objective on shares of Radius Health from $59.00 to $52.00 and set an “overweight” rating on the stock in a research note on Friday, November 2nd. Finally, BidaskClub cut shares of Radius Health from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $48.14.
The firm has a market capitalization of $683.55 million, a P/E ratio of -2.78 and a beta of 1.05. The company has a current ratio of 5.50, a quick ratio of 5.39 and a debt-to-equity ratio of 1.85.
In other news, major shareholder Growth N. V. Biotech bought 60,000 shares of the firm’s stock in a transaction on Monday, August 20th. The stock was bought at an average cost of $19.65 per share, for a total transaction of $1,179,000.00. Following the completion of the acquisition, the insider now directly owns 6,590,276 shares in the company, valued at approximately $129,498,923.40. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 3.42% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Trexquant Investment LP acquired a new stake in shares of Radius Health during the second quarter worth approximately $879,000. Artisan Partners Limited Partnership acquired a new stake in shares of Radius Health during the second quarter worth approximately $6,763,000. Senzar Asset Management LLC acquired a new stake in shares of Radius Health during the second quarter worth approximately $1,784,000. Sei Investments Co. boosted its holdings in shares of Radius Health by 20.9% during the second quarter. Sei Investments Co. now owns 88,078 shares of the biopharmaceutical company’s stock worth $2,595,000 after purchasing an additional 15,200 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of Radius Health by 15.8% during the second quarter. Swiss National Bank now owns 66,000 shares of the biopharmaceutical company’s stock worth $1,945,000 after purchasing an additional 9,000 shares during the period.
TRADEMARK VIOLATION NOTICE: This article was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2018/11/15/radius-health-rdus-shares-up-10-1.html.
About Radius Health (NASDAQ:RDUS)
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Featured Article: Tariff
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.